Apolipoprotein Changes Following Gender-Affirming Hormone Therapy: A Prospective Cohort Study
This prospective cohort study demonstrates that gender-affirming hormone therapy induces significant, gender-specific changes in apolipoprotein profiles among transgender individuals, alterations that are only partially reflected by standard lipid measurements and may offer additional insights into cardiovascular disease risk.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, doctors have understood that the heart and blood vessels rely on a delicate balance of fats and proteins circulating in the blood. Among these, certain proteins called apolipoproteins act as the essential managers of cholesterol, deciding whether it is safely transported or allowed to build up in artery walls. While standard blood tests measure the amount of fat itself, these protein managers tell a more detailed story about the risk of heart disease. This biological nuance becomes critically important for transgender individuals, who often undergo gender-affirming hormone therapy to align their physical bodies with their gender identity. These treatments, which involve introducing testosterone for those transitioning to a male identity or estrogen for those transitioning to a female identity, are known to shift the body's fat distribution and metabolism. Because heart disease risk is closely tied to how the body handles fats, medical guidelines recommend monitoring blood lipids during these treatments. However, the standard tests used for decades may not capture the full picture of how these powerful hormones reshape the complex protein machinery that protects or threatens the heart.
A team of researchers in Denmark set out to look deeper than the standard fat measurements, focusing specifically on how these protein managers change after one year of hormone therapy. They followed a group of 87 transgender individuals, dividing them into two main categories based on their treatment history. One group consisted of people who had never taken gender-affirming hormones before the study began, allowing the scientists to watch the changes happen from the very start. The other group included people who had already been on these hormones for some time, providing a snapshot of what the body looks like after long-term use. The researchers measured 16 different apolipoproteins, a comprehensive panel that goes far beyond the usual cholesterol numbers, alongside standard fat levels and body composition scans.
The results revealed that the body's response to hormones is complex and differs significantly depending on the direction of the transition. For the individuals starting testosterone therapy, the study found a distinct shift toward a profile that is generally considered less favorable for heart health. Their levels of ApoA-I, a key protein that helps remove cholesterol from the arteries, dropped significantly. At the same time, their levels of HDL, the "good" cholesterol, also fell. Interestingly, a specific component of a protein called Lp(a), which is known to be a strong independent risk factor for heart disease in the general population, also decreased. This drop in Lp(a) is a novel finding in this context and could potentially be a positive sign, as lower levels of this specific protein are usually linked to lower heart risk. However, the overall pattern suggested a coordinated change in how the body handles fats that standard blood tests might miss, as the usual measures of total cholesterol and triglycerides did not change dramatically.
In contrast, the individuals starting estrogen therapy showed a different set of changes. Their levels of ApoA-I increased, which is typically a sign of better heart protection. They also saw rises in other proteins like ApoJ and ApoL-I, which are involved in moving fats and managing inflammation, though their exact role in heart risk is less clear. A notable finding was an increase in components related to Lp(a), suggesting a potential rise in a specific type of risk factor that is often resistant to change. While standard fat levels remained largely stable for this group, the shifts in the protein managers were significant. The researchers also compared the new starters to those who had been on hormones for years. They found that the protein levels of the long-term users were similar to the new starters after one year, suggesting that many of these changes happen relatively quickly and then stabilize, though the small size of the long-term group makes this observation tentative.
The study highlights that the story of heart health during hormone therapy is not told just by the amount of fat in the blood, but by the specific proteins that carry it. The changes observed were only partly reflected in the standard lipid tests that doctors currently rely on, indicating that these protein markers could offer a more complete view of cardiovascular risk. The researchers noted that these findings are based on a relatively small group of people and that the study did not track actual heart events like heart attacks or strokes. Therefore, while the data shows clear biological shifts, it does not yet prove that these changes will lead to more or fewer heart problems in the long run. The work serves as a crucial first step, suggesting that measuring these specific proteins might eventually help doctors better understand and manage the heart health of transgender individuals undergoing life-affirming medical care.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.